Mizuho Reiterates Outperform on Syndax Pharmaceuticals
The target implies substantial upside, making this a notable bullish analyst view, though it is a reiterated opinion rather than a newly stated catalyst.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The target implies substantial upside, making this a notable bullish analyst view, though it is a reiterated opinion rather than a newly stated catalyst.
What happened, with direct paths to the underlying reporting
Mizuho reiterated its Outperform rating on SNDX and gave a $43 target, compared with the posted price of $13.10.
Target: $43
Posted price: $13.1
Analyst firm: Mizuho Securities
Analyst: Salim Syed
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.